BW

TERF2 polyclonal Antibody | BS60388

(No reviews yet) Write a Review
SKU:
BW-BS60388
Availability:
Usually ships in 5 working days
£732.00 - £1,098.00

Description

TERF2 polyclonal Antibody | BS60388 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB

Application Range: WB: 1:500~1:1000

Background: elomeric repeat binding factor 1 (TERF1, PIN2, TRF1, TRBF1) and telomeric repeat binding factor 2 (TERF2, TRF2, TRBF2) are present at telomeres throughout the cell cycle, where they regulate telomerase by acting in cis to limit the elongation of individual chromosome ends. Telomerase adds hexameric repeats of 5'-TTAGGG-3' to the ends of chromosomal DNA. This telomerase enzyme plays an influential role in cellular immortalization and cellular senescence. TRF1 negatively regulates telomere elongation, while TRF2 protects the chromosome ends by inhibiting end-to-end fusions. Down-regulation of TRF expression in tumor cells may contribute to cell immortalization and malignant progression. TRF1 has an acidic N-terminus while TRF2 has a basic N-terminus. TRF2 localizes in the nucleolus at G0 and S and diffuses out of the nucleolus in G2 phase. During mitosis TRF2 disperses from the condensed chromosomes and returns to the nucleolus at cytokinesis.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: TERF2 polyclonal Antibody detects endogenous levels of TERF2 protein.

Molecular Weight: ~ 67 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Telomeric repeat-binding factor 2; TTAGGG repeat-binding factor 2; Telomeric DNA-binding protein; TERF2; TRBF2, TRF2

Immunogen: A synthetic peptide corresponding to residues in Human TERF2.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway:

View AllClose